S100A7A and lung adenocarcinoma: Our data provide evidence that S100A15 aggravates metastatic progressing in lung adenocarcinoma in vivo and in vitro through DNA hypomethylation over its gene promoter region, and CTNNB1-centered down-stream mediators.